Streetbeat News

Analyst Ratings

TSHA

Canaccord Genuity analyst Whitney Ijem has reiterated a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a price target of $13.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:13 pm

ILMN

Canaccord Genuity analyst Kyle Mikson has reiterated a 'Buy' rating on Illumina (NASDAQ:ILMN) and maintained a price target of $300.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:12 pm

AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced that it will present positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm, an epinephrine sublingual film, at the Global Food Allergy Prevention Summit. If approved, Anaphylm could be the first oral candidate for the emergency treatment of severe allergic reactions, including anaphylaxis.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:11 pm

CLVR

Canaccord Genuity analyst Bobby Burleson has reiterated a 'Hold' rating on Clever Leaves Holdings (NASDAQ:CLVR) and maintained a price target of $0.8.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:11 pm

HLLY

Canaccord Genuity analyst Brian McNamara maintains a 'Buy' rating on Holley (NYSE:HLLY) and raises the price target from $5 to $6.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:10 pm

ACHR

Canaccord Genuity analyst Austin Moeller has reiterated a 'Buy' rating on Archer Aviation (NYSE:ACHR) and maintained a $9 price target.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:09 pm

AFRM

Affirm Holdings, Inc (NASDAQ:AFRM) stock is trading lower after Piper Sandler analyst Kevin J. Barker downgraded the stock from Neutral to Underweight with a price target of $11.00. Barker expects higher rates to pressure operating margins as AFRM needs to hold more loans on the balance sheet. He also expects tighter underwriting standards, increased pricing, and the re-introduction of student debt payments to cause a slowdown in revenue growth over the next year.

Portfolio Pulse from Anusuya Lahiri

July 06, 2023 | 12:09 pm

CARM

Evercore ISI Group has initiated coverage on CARISMA Therapeutics (NASDAQ:CARM) with an Outperform rating and a price target of $12.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:08 pm

RETA

TD Cowen analyst Tyler Van Buren has initiated coverage on Reata Pharmaceuticals (NASDAQ:RETA) with an Outperform rating and a price target of $140.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:07 pm

MDRX

Argus Research analyst Jasper Hellweg has downgraded Veradigm (NASDAQ:MDRX) from Buy to Hold.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:05 pm